Oramed Pharmaceuticals (ORMP) Retained Earnings (2011 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Retained Earnings came in at -$85.1 million in Q1 2026, up 53.8% YoY from -$55.3 million in Q1 2025, and up 31.04% on a QoQ basis from -$123.4 million in Q4 2025.
Oramed Pharmaceuticals (ORMP) Retained Earnings (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 16 years of Retained Earnings data on file, last reported at -$85.1 million in Q1 2026.
- Quarterly Retained Earnings rose 53.8% year-over-year to -$85.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$85.1 million (up 53.8% YoY) and the FY2025 annual result came in at -$123.4 million, up 30.11% from the prior year.
- Retained Earnings rose to -$85.1 million in Q1 2026, from -$123.4 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $317.0 million in Q1 2023 to a low of -$184.3 million in Q1 2025.
- A 5-year average of -$45.1 million and a median of -$156.0 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings tumbled 155.76% — and 2026, when it jumped 53.8%.
- Tracing ORMP's Retained Earnings over 5 years: stood at -$163.1 million in 2022, then advanced by 3.39% to -$157.6 million in 2023, then declined by 12.1% to -$176.6 million in 2024, then soared by 30.11% to -$123.4 million in 2025, then soared by 31.04% to -$85.1 million in 2026.
- The last three Retained Earnings figures came in at -$85.1 million (Q1 2026), -$123.4 million (Q4 2025), and -$122.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - | -6.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.97 Mn |
| Mar 31, 2026 | -85.12 Mn |
| Dec 31, 2025 | -123.44 Mn |
| Sep 30, 2025 | -122.58 Mn |
| Jun 30, 2025 | -170.97 Mn |
| Mar 31, 2025 | -184.26 Mn |
| Dec 31, 2024 | -176.62 Mn |
| Sep 30, 2024 | -166.43 Mn |
| Jun 30, 2024 | -146.81 Mn |
| Mar 31, 2024 | -156.02 Mn |
| Dec 31, 2023 | -157.56 Mn |
| Sep 30, 2023 | -170.89 Mn |
| Jun 30, 2023 | -167.67 Mn |
| Mar 31, 2023 | 316.97 Mn |
| Dec 31, 2022 | -163.08 Mn |
| Sep 30, 2022 | 307.88 Mn |
| Jun 30, 2022 | 300.71 Mn |
| Mar 31, 2022 | 298.83 Mn |
| Nov 30, 2021 | 292.44 Mn |
| Aug 31, 2021 | 230.20 Mn |